Home | Orthoiodosupplementation | Body | Disease | Special | Overviews

Cancer

• Breast Cancer
• Colon Cancer
• Liver Cancer
• Lung Cancer
• Ovarian Cancer
• Pancreatic Cancer
• Prostate Cancer
• Stomach Cancer
• Thyroid Cancer
• Various Cancers

IODINE AND OVARIAN CANCER

STADEL

Dietary iodine and risk of breast, endometrial, and ovarian cancer.

Stadel BV.

Lancet. 1976 Apr 24;1(7965):890-1.

[abstract only]

"Geographic differences in the rates of breast, endometrial, and ovarian cancer appear to be inversely correlated with dietary iodine intake. Endocrinological considerations suggest that a low dietary iodine intake may produce a state of increased effective gonadotrophin stimulation, which in turn may produce a hyperoestrogenic state characterised by relatively high production of oestrone and oestradiol and a relatively low oestriol to oestrone plus oestradiol ratio. This altered endocrine state may increase the risk of breast, endometrial, and ovarian cancer. Increasing dietary iodine intake may reduce the risk of these cancers."

DWYER

Sodium iodide symporter-mediated radioiodide imaging and therapy of ovarian tumor xenografts in mice. 

Dwyer RM, Bergert ER, O'Connor MK, Gendler SJ, Morris JC.

Gene Ther. 2006 Jan;13(1):60-6.

"Ovarian cancer represents the fifth leading cause of cancer death among women in the United States, with >16,000 deaths expected this year. This study was carried out to investigate the potential of sodium iodide symporter (NIS)-mediated radioiodide therapy as a novel approach for ovarian cancer treatment. Radioiodide is routinely and effectively used for the treatment of benign and malignant thyroid disease as a result of native thyroidal expression of NIS, which mediates iodide uptake. In vitro gene transfer studies in ovarian cancer cells revealed a 12- and five-fold increase in iodide uptake when transduced with Ad/CMV/NIS or Ad/MUC1/NIS, respectively. Western blot/immunohistochemistry confirmed NIS protein expression. In vivo ovarian tumor xenografts were infected with the adenoviral constructs. (123)I imaging revealed a clear image of the CMV/NIS-transduced tumor, with a less intense image apparent following infection with MUC1/NIS. Therapeutic doses of (131)I following CMV/NIS infection caused a mean 53% reduction in tumor volume (P<0.0001). MUC1/NIS-transduced tumors did not regress, although at 8 weeks following therapy, tumor volume was significantly less that of control animals (166 versus 332%, respectively, P<0.05). This study represents a promising first step investigating the potential for NIS-mediated radioiodide imaging and therapy of ovarian tumors."

 Home | Orthoiodosupplementation | Body | Disease | Special Topics | Overviews  

The Iodine Group | Books | Disclaimers | Contact Us | Search  

  Copyright: Zoe, 2006.